Journal of Vaccine Research 2024, Vol.14, No.3, 135-146 http://medscipublisher.com/index.php/jvr 145 advance in vaccine technology and research, the impact on global health can be profound, reducing morbidity and mortality rates and promoting health equity across diverse populations. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Ammon A., and Monné X.P., 2018, Vaccines, trust and European public health, Eurosurveillance, 23(17): 18-21. https://doi.org/10.2807/1560-7917.ES.2018.23.17.18-00210 PMid:29717694 PMCid:PMC5930725 Borghi L., and Riva E., 2021, Was aldo castellani the inventor of combined and polyvalent vaccines?, Vaccine, 39(31): 4285-4290. https://doi.org/10.1016/j.vaccine.2021.07.062 PMid:34373123 Camacho L., and Codeço C., 2020, Vaccines in public health, Cadernos de Saude Publica, 36: e00199920. https://doi.org/10.1590/0102-311x00199920 PMid:32876102 Caplan A., and Bateman-House A., 2020, Transparency is key to ethical vaccine research, Science, 370: 1423-1424. https://doi.org/10.1126/science.abf7809 PMid:33335058 Chen Y.T., Ng X., Petigara T., Aggarwal J., Bhaloo J., Goveia M.G., Johnson D.R., and Marshall G.S., 2020, 1400, Physician attitudes towards combination vaccine use in infants up to 24 months of age in the United States (US), Open Forum Infectious Diseases, 7(Suppl 1): 708. https://doi.org/10.1093/ofid/ofaa439.1582 PMCid:PMC7777494 Coccia M., Collignon C., Hervé C., Chalon A., Welsby I., Detienne S., van Helden M.V., Dutta S., Genito C.J., Waters N., Van Deun K., Smilde A., van den Berg R.A., Franco D., Bourguignon P., Morel S., Garçon N., Lambrecht B., Goriely S., van der Most R.G., and Didierlaurent A., 2017, Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity, NPJ Vaccines, 2(1): 25. https://doi.org/10.1038/s41541-017-0027-3 PMid:29263880 PMCid:PMC5627273 Esteves-Jaramillo, A., and Schmitt, H.J., 2022, Combination vaccines, VacciTUTOR, 3(1): 63-72. https://doi.org/10.33442/vt202128 Gause K.T., Wheatley, A., Cui J., Yan Y., Kent S., and Caruso F., 2017, Immunological principles guiding the rational design of particles for vaccine delivery, ACS Nano, 11(1): 54-68. https://doi.org/10.1021/acsnano.6b07343 PMid:28075558 Grady C., Shah S., Miller F., Danis M., Nicolini M., Ochoa J., Taylor H.A., Wendler D., and Rid A., 2020, So much at stake: ethical tradeoffs in accelerating SARSCoV-2 vaccine development, Vaccine, 38(41): 6381-6387. https://doi.org/10.1016/j.vaccine.2020.08.017 PMid:32826103 PMCid:PMC7418641 Jecker N., Wightman A., and Diekema D., 2021, Vaccine ethics: an ethical framework for global distribution of COVID-19 vaccines, Journal of Medical Ethics, 47(5): 308-317. https://doi.org/10.1136/medethics-2020-107036 PMid:33593876 Kazi A., Chuah C., Majeed A., Leow C., Lim B., and Leow C., 2018, Current progress of immunoinformatics approach harnessed for cellular-and antibody-dependent vaccine design, Pathogens and Global Health, 112: 123-131. https://doi.org/10.1080/20477724.2018.1446773 PMid:29528265 PMCid:PMC6056828 Kurosky S., Davis K., and Krishnarajah G., 2017, Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States, Human Vaccines and Immunotherapeutics, 13(11): 2494-2502. https://doi.org/10.1080/21645515.2017.1362515 PMid:28881166 PMCid:PMC5703402 Leunda A., and Pauwels K., 2019, GMO regulatory aspects of novel investigational vaccine candidates, Vaccines-the History and Future, 2019: 1-18. https://doi.org/10.5772/INTECHOPEN.85341 PMCid:PMC6384694 Li Z., Xu J., Tan H., Zhang C., Chen J., Ni L., Yun X., Huang Y., and Wang W., 2020, Safety of pentavalent DTaP-IPV/Hib combination vaccine in post-marketing surveillance in Guangzhou, China, from 2011 to 2017, International Journal of Infectious Diseases, 93: 72. https://doi.org/10.1016/j.ijid.2020.07.019 PMid:32795602
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==